Roquefort cheese proteins inhibit Chlamydia pneumoniae propagation and LPS-induced leukocyte migration

ScientificWorldJournal. 2013 Apr 28:2013:140591. doi: 10.1155/2013/140591. Print 2013.

Abstract

Inflammation in atherosclerosis, which could be associated with some subclinical infections such as C. pneumoniae, is one of the key factors responsible for the development of clinical complications of this disease. We report that a proprietary protein extract isolated from Roquefort cheese inhibits the propagation of C. pneumoniae in a human HL cell line in a dose-dependent manner, as revealed by the immunofluorescence analysis. These changes were accompanied by a significant reduction in the infective progeny formation over the protein extract range of 0.12-0.5 μg/mL. Moreover, short term feeding of mice with Roquefort cheese (twice, 10 mg per mouse with an interval of 24 hours) led to the inhibition of the migration of peritoneal leukocytes caused by intraperitoneal injection of E. coli lipopolysaccharide. These changes were complemented by a reduction in neutrophil count and a relative increase in peritoneal macrophages, suggesting that ingestion of Roquefort could promote regenerative processes at the site of inflammation. The ability of this protein to inhibit propagation of Chlamydia infection, as well as the anti-inflammatory and proregenerative effects of Roquefort itself, may contribute to the low prevalence of cardiovascular mortality in France where consumption of fungal fermented cheeses is the highest in the world.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cell Movement / drug effects
  • Cell Proliferation / drug effects
  • Cheese / microbiology*
  • Chlamydophila pneumoniae / cytology
  • Chlamydophila pneumoniae / drug effects*
  • Inflammation / diet therapy*
  • Inflammation / immunology*
  • Inflammation / pathology
  • Leukocytes / drug effects
  • Leukocytes / immunology*
  • Lipopolysaccharides*
  • Mice
  • Milk Proteins / administration & dosage*
  • Treatment Outcome

Substances

  • Lipopolysaccharides
  • Milk Proteins